Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Dose Psilocybin for Major Depressive Disorder (MDD)
NCT03866174Phase 2Completed
- Sponsor
- Usona Institute
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in major depressive disorder (MDD) (2 arms), sponsored by Usona Institute. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Day 43. Started Jan 2020; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03866174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866174.